Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis
October 31, 2016 | Press Releases
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
October 26, 2016 | Press Releases
Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
October 10, 2016 | Press Releases
Cellceutix Announces Appointment of Vice President for Regulatory Affairs
September 16, 2016 | Press Releases
Vitae Acquisition & Cellceutix Provides Business Update and Timeline of Upcoming Milestone
September 15, 2016 | Press Releases
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
September 14, 2016 | Press Releases
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
August 30, 2016 | Press Releases
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
August 3, 2016 | Press Releases
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
July 21, 2016 | Press Releases
